The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
RTN4B‐mediated suppression of Sirtuin 2 activity ameliorates β‐amyloid pathology and cognitive impairment in Alzheimer’s disease mouse model
Abstract
Sirtuin 2 (SIRT2) is an NAD+ dependent deacetylase that is the most abundant sirtuin protein in the brain. Accumulating evidence revealed the role of SIRT2 in a wide range of biological processes and age‐related diseases. However, the pivotal mechanism of SIRT2 played in Alzheimer's disease (AD) remains unknown. Here, we report that pharmacological inactivation of SIRT2 has a beneficial effect in AD. The deacetylase inhibitor of SIRT2 rescued the cognitive impairment in amyloid precursor protein/presenilin 1 transgenic mouse ( APP / PS1 mouse), and the BACE1 cleavage was weakened to reduce the β‐amyloid (Aβ) production in the hippocampus. Moreover, we firstly identified that Reticulon 4B (RTN4B) played a crucial role between SIRT2/BACE1 regulation in AD. RTN4B, as a deacetylation substrate for SIRT2, the deacetylation by SIRT2 drived the ubiquitination and degradation of RTN4B and then the disturbed RTN4B interacted with and influenced the expression of BACE1. When we overexpressed RTN4B in neurons of the hippocampus in the AD mouse model, the abnormal Aβ accumulation and cognitive impairment were ameliorated, consistent with the results of SIRT2 inhibition in vivo. Moreover, we showed that the regulatory effect of SIRT2 on BACE1 is dependent on RTN4B. When RTN4B was knocked down, the effects of SIRT2 inhibition on the BACE1 level, Aβ pathology, and AD‐liked behaviors were also blocked. Collectively, we provide evidence that SIRT2 may be a potential target for AD; the new found SIRT2/RTN4B/BACE1 pathological pathway is one of the critical mechanisms for the improvement of SIRT2 on AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bai et al. (Bai et al., 2022) and Wang et al. (Wang et al., 2020) demonstrated that whole-body SIRT2 knockout or inhibition reduces amyloid pathology by shifting APP processing toward the non-amyloidogenic pathway, either through increased APP acetylation or inhibition of BACE1 activity.”
From Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer’s disease (2025) · cites this paper as Wang et al., 2020
In the citing paper
“Therefore, we propose that neuron SIRT2 deletion may be beneficial by reducing Aβ production (Bai et al., 2022;Wang et al., 2020), while microglia-specific SIRT2 deletion may impair Aβ degradation (Chen et al., 2023); present study), thereby exacerbating the pathology.”
From Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer’s disease (2025) · cites this paper as Wang et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990 · cited 1×
“…AD, including the extracellular deposition of amyloid-β (Aβ) peptides and intracellular neurofibrillary tau tangles, are closely associated with synapse and neuron loss, ultimately memory impairment in AD (De Strooper & Karran, 2016; Palop & Mucke, 2016; Zott, Busche, Sperling, & Konnerth, 2018).”
BackgroundThe BioPlex network: a systematic exploration of the human interactome
Huttlin, E. L., Ting, L., Bruckner, R. J., Gebreab, F., Gygi, M. P., Szpyt, J., Tam, S., Zarraga, G., Colby, G., Baltier, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.043 · Cited by 1,425 · cited 1×
“Besides, a previous study that using metabolic labeling quantitative MS also suggested that RTN4 may transiently target SIRT2 (Budayeva & Cristea, 2016), and this possible interaction was also identified in other proteomic studies (Huttlin et al., 2015), supporting our results.”
ResultElevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729
Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease
Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002) · Annals of Neurology · doi:10.1002/ana.10208 · Cited by 562
Maturation and Endosomal Targeting of β-Site Amyloid Precursor Protein-cleaving Enzyme
Huse, J. T., Pijak, D. S., Leslie, G. J., Lee, V. M.-Y., & Doms, R. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004175200 · Cited by 402
A resurrection of aducanumab for Alzheimer's disease
Schneider, L. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30480-6 · Cited by 286 · cited 1×
“However, the resurrection of Aducanumab (Biogen), which targets Aβ, combining with the exclusive genetic evidence, has reignited the hope for Aβ-targeted therapy (Schneider, 2020; Selkoe, 2019).”
BackgroundAlzheimer disease and aducanumab: adjusting our approach
Selkoe, D. J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0205-1 · Cited by 208 · cited 1×
“However, the resurrection of Aducanumab (Biogen), which targets Aβ, combining with the exclusive genetic evidence, has reignited the hope for Aβ-targeted therapy (Schneider, 2020; Selkoe, 2019).”
BackgroundKo, M. H., & Puglielli, L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804901200 · Cited by 111
Research works printed but not linked: 28
- 10.3233/JAD-151135 · DOI · Paper page
- 10.1074/mcp.M116.061333 · DOI
- 10.1038/35000219 · DOI · Paper page
- 10.1126/science.1175371 · DOI · Paper page
- 10.1074/jbc.M113.480079 · DOI
- 10.1038/s41386-019-0503-8 · DOI · Paper page
- 10.1002/emmm.201302451 · DOI · Paper page
- 10.1038/nature08197 · DOI · Paper page
- 10.1016/j.tips.2019.09.003 · DOI
- 10.1038/nm1088 · DOI · Paper page
- 10.1038/srep35391 · DOI · Paper page
- 10.1016/j.molcel.2013.07.002 · DOI · Paper page
- 10.1016/j.arr.2018.03.006 · DOI
- 10.1089/ars.2016.6662 · DOI
- 10.1093/hmg/ddr326 · DOI · Paper page
- 10.1111/j.1460-9568.2006.05005.x · DOI
- 10.1038/nrn.2016.141 · DOI · Paper page
- 10.1016/j.jalz.2012.02.003 · DOI
- 10.1007/s00702-013-1045-6 · DOI
- 10.1111/acel.13109 · DOI
- 10.1523/JNEUROSCI.1588-14.2014 · DOI
- Silva D. F., 2016, Mitochondrial metabolism power SIRT2‐dependent deficient traffic causing Alzheimer's‐disease related pathology, Molecular Neurobiology
- 10.1016/j.arr.2019.100961 · DOI · Paper page
- 10.1002/embj.201387224 · DOI · Paper page
- 10.2174/1567205015666181109103742 · DOI
- World Health Organization, 2015, The epidemiology and impact of dementia
- 10.1146/annurev-neuro-080317-061725 · DOI · Paper page
- 10.1038/35000219 · DOI · Paper page
Cited by
The sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
Self-citationSola-Sevilla, N., Garmendia-Berges, M., Aleixo, M., Mera-Delgado, M., Solas, M., Tordera, R. M., García-Carracedo, L., Expósito, S., Anaya-Cubero, E., Fernández-Irigoyen, J., et al. (2025) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2025.06.016 · Cited by 5
Metadata
- Authors
- Wang, Y., Yang, J., Hong, T.-T., Sun, Y., Huang, H., Chen, F., Chen, X., Chen, H., Dong, S., Cui, L., & Yang, T.
- Affiliations
- Key Laboratory of Biomedical Information Engineering of Ministry of Education Biomedical Informatics & Genomics Center School of Life Science and Technology Xi'an Jiaotong University Xi'an China
- Guangdong Key Laboratory of Age‐Related Cardiac and Cerebral Diseases Affiliated Hospital of Guangdong Medical University Zhanjiang China
- Department of Pharmacology and Neuroscience University of North Texas Health Science Center Fort Worth TX USA
- Institute of Plastic Surgery Affiliated Hospital of Guangdong Medical University Zhanjiang China
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2020-07-23
- Volume
- 19
- Issue
- 8
- ISSN
- 1474-9718
- 1474-9726
- Cited by
- 60
- References
- 10
- Language
- en
- Funders
- National Natural Science Foundation of China (81671181)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RTN4B‐mediated suppression of Sirtuin 2 activity ameliorates β‐amyloid pathology and cognitive impairment in Alzheimer’s disease mouse model. https://app.cochat.ai/papers/10.1111/acel.13194
- The paper
- Wang, Y., Yang, J., Hong, T.-T., Sun, Y., Huang, H., Chen, F., Chen, X., Chen, H., Dong, S., Cui, L., & Yang, T. (2020). RTN4B‐mediated suppression of Sirtuin 2 activity ameliorates β‐amyloid pathology and cognitive impairment in Alzheimer’s disease mouse model. Aging Cell. https://doi.org/10.1111/acel.13194
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.